What is Hot Melt Extrusion, And How Can It Benefit Your Drug Product?

By Ania VanDyke, Associate Director Business Development, Contract Manufacturing

Poor solubility remains a persistent roadblock in drug development, frequently stalling promising active pharmaceutical ingredients (APIs) during formulation. Hot-melt extrusion (HME) has emerged as a premier enabling technology to overcome these bioavailability challenges by converting crystalline powder blends into stable amorphous solid dispersions (ASDs). The process utilizes co-rotating twin-screw extruders to apply controlled thermal and mechanical energy, dispersing the API uniformly within a specialized protective polymer matrix. This disruption of the drug’s crystal lattice allows the resulting formulation to release therapeutic nanoparticles upon dissolution, dramatically boosting absorption rates.

Beyond therapeutic performance, HME offers significant operational advantages over alternative methods like spray drying. Operating as a solvent-free, continuous manufacturing process, it streamlines workflows, features a compact footprint, and simplifies commercial scale-up. Gain deeper technical insights into excipient screening and process controls by reading the complete article.